AGTC Genomics Advances Local Genomics Technology Development in Malaysia
- May 7
- 2 min read
Kuala Lumpur, Malaysia — AGTC Genomics was proud to contribute to Amazon Web Services Genomics Community Day Malaysia, a major gathering of more than 130 leaders and professionals from healthcare, academia, research, and industry, focused on advancing the future of AI-driven precision medicine.
Hosted at the Amazon Web Services Malaysia office, the event served as a platform for meaningful discussions on how artificial intelligence, scalable cloud infrastructure, and genomics can be integrated to strengthen clinical decision-making, accelerate translational research, and improve equitable access to precision healthcare across Malaysia and the region.
AGTC Genomics Founder and CEO, Prof. Dr. Chee-Onn Leong, highlighted a critical message during the session: the difference between being a technology user and being a technology developer.
“Many countries can adopt technology, purchase platforms, and become users of innovation. But true long-term impact comes when we build our own capabilities—developing our own algorithms, genomic databases, clinical interpretation frameworks, and solutions that are relevant to our own population,” said Prof. Leong.
He emphasized that in precision medicine, clinical utility must remain the central goal.
“AI is only as good as the data behind it. If we rely entirely on external datasets and imported technologies, we risk building healthcare systems that may not fully reflect the realities of Malaysian and Southeast Asian populations. Precision medicine must be measured not just by technological advancement, but by real clinical utility, equitable access, and better outcomes for patients.”
Malaysia has made significant progress through national initiatives such as MyGenom, pangenome projects, and the broader adoption of clinical genomics. However, AGTC Genomics believes the next phase of growth must focus on developing local capabilities that translate genomic insights into actionable patient care.
As one of Malaysia’s leading precision medicine companies, AGTC Genomics continues to invest in advanced genomics infrastructure, AI-powered bioinformatics, clinical interpretation systems, and locally validated precision medicine solutions that improve accessibility and affordability for patients nationwide.
The event was honored by the presence of Datuk Dr. Nor Fariza Ngah, Deputy Director General of the Ministry of Health Malaysia, as Guest of Honour, alongside distinguished speakers from leading healthcare and academic institutions.
The session also featured ecosystem partners including PacBio, Oxford Nanopore Technologies, Lifebit, Invisibl Cloud, and Xcoo, showcasing technologies that support real-world genomics implementation across diagnostics, research, and clinical care.
“Strong collaboration between industry, academia, healthcare, and government creates valuable learning opportunities that build sustainable local capacity and capability. The future of precision medicine in Malaysia will depend on how boldly we choose to build—not just adopt,” Prof. Leong added.
AGTC Genomics remains committed to advancing precision medicine through innovation, collaboration, and the belief that better healthcare begins with the right data, the right algorithm, and the right patient.
About AGTC Genomics
AGTC Genomics is Malaysia’s leading precision medicine and advanced genomics company, providing comprehensive genomics solutions for oncology, rare diseases, hereditary conditions, pharmacogenomics, infectious diseases, and preventive healthcare. With ISO 15189 and College of American Pathologist (CAP)-accredited advanced genomics laboratories and state-of-the-art sequencing platforms, AGTC Genomics is committed to making precision medicine more accessible, affordable, and impactful across Malaysia and the region.
Comments